Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human clinical study of autologous induced pluripotent stem cell (iPSC) technology in South Korea

Next Previous
Trial Profile

First-in-human clinical study of autologous induced pluripotent stem cell (iPSC) technology in South Korea

Status: Not stated
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous-induced-pluripotent-stem-cell-based-therapy-Karis-Bio (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Peripheral arterial disorders
  • Focus First in man; Therapeutic Use

Most Recent Events

  • 29 Apr 2025 New trial record
  • 15 Apr 2025 According to a Cellino media release, partnership between Cellino and Karis bio focuses on industrializing autologous iPSC manufacturing, with plans to expand into Phase 2 trials through Karis Bio, USA (headquartered in Atlanta) in the U.S.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top